Stock listing

Lang & Schwarz:A2P5PP Larimar Therapeutics, Inc. Aktie

German listing (Lang & Schwarz) of Larimar Therapeutics, Inc. · home listing NASDAQ:LRMR

Follow Larimar Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:LRMR

$3.14 USD -0.08 (-2.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LRMR

Past year -6.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.96 – $3.22 USDNov 20, 2026
Volume
1.71M sharesNov 20, 2026
Market cap
$328.6M USDAt the close on Nov 20, 2026 · price × 104.6M shares outstanding
52-week range
$1.92 – $6.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.11M USDMedian day 1.14M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Larimar Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LRMR · Home$3.14 USD-0.085 (-2.6%)1,707,224$3.15$3.22$2.96$3.225Close on Nov 20, 2026
Frankfurt:ZA71€2.86 EUR-0.10 (-3.4%)—€2.86€2.86€2.86€2.96Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LRMR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.14-0.085-2.6%$3.15$3.22$2.961,707,224
$3.225+0.235+7.9%$2.95$3.345$2.931,405,708
$2.99-0.01-0.3%$3.01$3.13$2.901,376,889
$3.00-0.02-0.7%$3.02$3.29$2.8852,737,345
$3.02+0.32+11.9%$3.01$3.075$2.8352,531,399
$2.70-0.03-1.1%$2.71$2.76$2.511,190,176
$2.73+0.04+1.5%$2.69$2.83$2.601,156,891
$2.69+0.16+6.3%$2.58$2.735$2.46737,802
$2.53+0.14+5.9%$2.47$2.58$2.37693,309
$2.39+0.07+3.0%$2.355$2.475$2.30973,590
$2.32-0.44-15.9%$2.76$2.83$2.2651,772,574
$2.76+0.22+8.7%$2.60$2.78$2.5751,991,446
$2.54+0.17+7.2%$2.39$2.62$2.371,648,267
$2.37-0.10-4.0%$2.49$2.566$2.34667,387
$2.47-0.20-7.5%$2.64$2.655$2.42777,010
$2.67+0.13+5.1%$2.57$2.73$2.5581,026,963
$2.54+0.15+6.3%$2.385$2.55$2.31809,332
$2.39+0.15+6.7%$2.25$2.41$2.211,203,992
$2.24-0.11-4.7%$2.36$2.39$2.181,309,558
$2.35+0.08+3.5%$2.27$2.37$2.221,144,000
$2.27-0.15-6.2%$2.40$2.509$2.2351,763,700
$2.42-0.02-0.8%$2.40$2.54$2.391,512,900
$2.44+0.32+15.1%$2.12$2.49$2.101,810,000
$2.12+0.135+6.8%$1.99$2.175$1.961,231,300
$1.985-0.005-0.3%$2.05$2.07$1.9151,692,000
$1.99-0.10-4.8%$2.09$2.115$1.956,174,400
$2.09-0.07-3.2%$2.15$2.22$2.062,257,000
$2.16-0.37-14.6%$2.53$2.53$2.132,565,100
$2.53-0.14-5.2%$2.66$2.69$2.53950,200
$2.67-0.03-1.1%$2.68$2.74$2.62867,600
$2.70-0.05-1.8%$2.72$2.74$2.611,190,400
$2.75-0.03-1.1%$2.77$2.835$2.72718,000
$2.78-0.08-2.8%$2.88$2.90$2.74828,100
$2.86-0.10-3.4%$2.96$3.04$2.775886,000
$2.96-0.10-3.3%$3.11$3.11$2.92835,000
$3.06-0.135-4.2%$3.20$3.20$3.04858,300
$3.195+0.055+1.8%$3.13$3.225$3.0751,497,000
$3.14-0.03-0.9%$3.13$3.20$3.1151,041,600
$3.17+0.095+3.1%$3.04$3.231$3.031,672,800
$3.075-0.245-7.4%$3.32$3.34$3.023,046,500
$3.32-0.545-14.1%$3.85$3.86$3.3053,632,000
$3.865+0.045+1.2%$3.82$3.90$3.712,718,600
$3.82-0.01-0.3%$3.91$3.965$3.815702,900
$3.83+0.04+1.1%$3.84$3.885$3.78578,000
$3.79-0.01-0.3%$3.81$3.88$3.751,640,900
$3.80-0.13-3.3%$3.93$4.12$3.801,195,800
$3.93+0.02+0.5%$3.93$3.97$3.8251,951,900
$3.91+0.13+3.4%$3.86$3.94$3.70856,600
$3.78-0.14-3.6%$3.93$3.98$3.741,169,100
$3.92+0.07+1.8%$3.91$4.07$3.852,127,200
$3.85-0.02-0.5%$3.82$3.86$3.74870,900
$3.87-0.205-5.0%$4.03$4.17$3.83977,400
$4.075+0.245+6.4%$3.76$4.08$3.721,040,600
$3.830.000.0%$3.82$3.85$3.79391,900
$3.83-0.04-1.0%$3.90$3.90$3.774683,700
$3.87-0.07-1.8%$3.96$4.075$3.822515,300
$3.94+0.12+3.1%$3.78$3.95$3.77755,300
$3.82-0.19-4.7%$3.98$4.00$3.811,065,500
$4.01-0.04-1.0%$4.03$4.08$3.98641,500
$4.05-0.12-2.9%$4.16$4.16$4.02672,900
$4.17+0.01+0.2%$4.14$4.18$4.02702,100
$4.16+0.11+2.7%$4.08$4.235$4.081,082,141
$4.05-0.13-3.1%$4.23$4.23$3.93945,554
$4.18+0.02+0.5%$4.20$4.21$4.085699,400
$4.16-0.09-2.1%$4.21$4.21$3.9751,158,000

Splits

1 split · NASDAQ:LRMR · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
Lang & Schwarz:A2P5PP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Larimar Therapeutics, Inc. news

Larimar Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 78 in all · newest Nov 16, 2026 · oldest 2020
Decks
55 decks · latest Nov 9, 2026

Where Larimar Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LRMR · Home listingNASDAQUnited StatesUSD
LS Exchange:A2P5PPLS ExchangeGermanyEUR
gettex:ZA71gettexGermanyEUR
BOATS:LRMRBOATSUnited StatesUSD
Lang & Schwarz:A2P5PP · This pageLang & SchwarzGermanyEUR
Tradegate:ZA71TradegateGermanyEUR
Dusseldorf:ZA71DusseldorfGermanyEUR
Frankfurt:ZA71FrankfurtGermanyEUR
Stuttgart:ZA71StuttgartGermanyEUR

Valuation

Price/book 3.2× against a median of 1.8×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$204.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.48

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.3Mn/a9.6×n/a1.8×−214.9%0.0×n/a
Foresee Pharmaceuticals Co., Ltd. · TPEX:6576US$319.8MUS$303.4M469×21.2×n/a8.3×4.8%0.3×n/a
Atea Pharmaceuticals, Inc. · NASDAQ:AVIRUS$317.6MUS$126.6Mn/an/an/a1.8×n/a0.0×0.86
GI Innovation, Inc. · KRX:358570US$315.9MUS$286.8Mn/an/an/a4.4×n/a0.0×n/a
MapLight Therapeutics, Inc. · NASDAQ:MPLTUS$313.9MUS$29.84Mn/an/an/a0.7×n/a0.0×1.28
Median of the othersUS$324.2MUS$241.7M469×1,151×3.4×1.8×−214.9%0.1×1.07

Forecasts

9 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
14.20 USD · Analysts' mean
EPS, year to Dec 2026
-1.18 · 4 analysts

Team and board

Officers

OfficerRole
Carole Ben-MaimonChief Executive Officer
Michael CelanoCHIEF FINANCIAL OFFICER
John HarlowPresident and Chief Operating Officer
Adrienne Clements-EganVice President, Bioanalytics and Developability
Francis Michael ConwayVICE PRESIDENT AND CONTROLLER
Frank NazzarioVice President, Commercial
Jennifer JohanssonVice President, Legal and Compliance
John BermanVice President of Finance and Administration
Keith E. LynchVice President, CMC Technical Operations
Mohamed HamdaniVice President, Statistics and Quantitative Sciences
Noreen SchererVice President of Clinical Operations
Gopi ShankarChief Development Officer
Rusty ClaytonChief Medical Officer

Board

DirectorRole
Joseph TruittBOARD CHAIR
Frank E. Thomas
Jeffrey Sherman
Jonathan Leff
Tom Hamilton

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−0.7%
Q2 2026Aug 4, 2026 · Before open+3.3%
Q1 2026May 14, 2026 · Before open−5.1%
Q4 2025Mar 18, 2026+2.0%
Q3 2025Nov 5, 2025 · Before open−15.3%
Q2 2025Aug 14, 2025 · Before open+14.5%
Q1 2025Apr 30, 2025 · Before open+10.9%
Q4 2024Mar 12, 2025 · Before open+1.5%
Q3 2024Oct 30, 2024 · Before open+8.7%
Q2 2024Aug 7, 2024 · Before open−6.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−9.4%
Q4 2023Mar 14, 2024 · After close+0.1%
Q3 2023Nov 14, 2023 · After close+14.4%
Q2 2023Aug 10, 2023 · Before open−4.8%
Q1 2023May 15, 2023 · Before open−29.1%
Q4 2022Mar 14, 2023 · Before open+3.0%
Q3 2022Nov 10, 2022 · Before open+3.7%
Q2 2022Aug 11, 2022 · After close+7.1%
Q1 2022May 12, 2022 · Before open−7.9%
Q4 2021Mar 25, 2022 · Before open−0.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck38 slidesNov 9, 2026
Investor Presentation (August 2026)Investor deck40 slidesAug 4, 2026
Corporate Update (June 2026)Corporate update26 slidesJun 29, 2026
Investor Presentation (May 2026)Investor deck54 slidesMay 14, 2026
Investor Presentation (March 2026)Investor deck54 slidesMar 9, 2026
Investor Presentation (February 2026)Investor deck54 slidesFeb 24, 2026
Investor Presentation (January 2026)Investor deck54 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck52 slidesNov 10, 2025
Investor Presentation (October 2025)Investor deck52 slidesOct 14, 2025
Corporate Update (September 2025)Corporate update18 slidesSep 29, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (August 2025)Investor deck58 slidesAug 14, 2025
Corporate Update (June 2025)Corporate update14 slidesJun 23, 2025
Investor Presentation (June 2025)Investor deck58 slidesJun 23, 2025
Investor Presentation (May 2025)Investor deck58 slidesMay 5, 2025
Investor Presentation (March 2025)Investor deck58 slidesMar 24, 2025
Investor Presentation (January 2025)Investor deck59 slidesJan 10, 2025
Corporate Update (December 2024)Corporate update59 slidesDec 16, 2024
Investor Presentation (November 2024)Investor deck50 slidesNov 18, 2024
Investor Presentation (October 2024)Investor deck45 slidesOct 30, 2024
Investor Presentation (August 2024)Investor deck45 slidesAug 7, 2024
Investor Presentation (June 2024)Investor deck45 slidesJun 10, 2024
Investor Presentation (May 2024)Investor deck44 slidesMay 20, 2024
Investor Presentation (May 2024)Investor deck46 slidesMay 9, 2024
Investor Presentation (March 2024)Investor deck47 slidesMar 11, 2024
Leerink Partners Global Healthcare Conference 2024Conference19 slidesMar 11, 2024
Corporate Update (February 2024)Corporate update22 slidesFeb 12, 2024
Investor Presentation (February 2024)Investor deck45 slidesFeb 12, 2024
Investor Presentation (November 2023)Investor deck44 slidesNov 14, 2023
Investor Presentation (August 2023)Investor deck44 slidesAug 14, 2023
Corporate Update (July 2023)Corporate update12 slidesJul 25, 2023
Investor Presentation (June 2023)Investor deck43 slidesJun 1, 2023
Corporate Update (May 2023)Corporate update15 slidesMay 15, 2023
Investor Presentation (March 2023)Investor deck33 slidesMar 14, 2023
Investor Presentation (January 2023)Investor deck33 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck31 slidesNov 10, 2022
Investor Presentation (October 2022)Investor deck32 slidesOct 20, 2022
Corporate Update (September 2022)Corporate update31 slidesSep 14, 2022
Investor Presentation (August 2022)Investor deck34 slidesAug 11, 2022
Investor Presentation (May 2022)Investor deck34 slidesMay 12, 2022
Investor Presentation (March 2022)Investor deck34 slidesMar 25, 2022
Investor Presentation (February 2022)Investor deck34 slidesFeb 28, 2022
Investor Presentation (November 2021)Investor deck36 slidesNov 12, 2021
Investor Presentation (August 2021)Investor deck36 slidesAug 12, 2021
Investor Presentation (July 2021)Investor deck36 slidesJul 1, 2021
Investor Presentation (May 2021)Investor deck36 slidesMay 18, 2021
Corporate Update (May 2021)Corporate update22 slidesMay 11, 2021
Investor Presentation (December 2020)Investor deck31 slidesDec 8, 2020
Investor Presentation (November 2020)Investor deck28 slidesNov 10, 2020
Investor Presentation (August 2020)Investor deck23 slidesAug 6, 2020
Investor Presentation (June 2020)Investor deck21 slidesJun 3, 2020

This page holds 50 of 55 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of shares of common stock and pre-funded warrants
Announced: US$75M · J.P. Morgan +1
Dealers: J.P. Morgan (co-lead), Guggenheim Securities (co-lead)
Use of proceeds: Development of nomlabofusp, working capital and general corporate purposes, including R&D and commercialization expenses
Feb 25, 2026
Public offering of common stock
Closed: US$69M raised · US$3.2 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), William Blair (co-lead)
Use of proceeds: Development of nomlabofusp and other pipeline candidates, working capital and general corporate purposes including R&D and pre-commercialization
Jul 31, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as ZAFGEN, INC. Priced at US$16.00 a share on Jun 18, 2014.

Price
US$16.00 a share
Shares offered
6,000,000 shares of common stock
Offering size
US$96 million
Underwriters' option
Up to 900,000 more shares
Underwriters
Leerink Partners, Cowen and Company, Canaccord Genuity, JMP Securities · In the order on the cover
Shares delivered
On or about Jun 24, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceJan 31, 2014
Filed publiclyApr 18, 2014
Amended 5 timesNewest Jun 16, 2014
Shares registered with an exchangeJun 18, 2014
Declared effective by the SECJun 18, 2014
Final prospectus, with the priceJun 19, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Jun 19, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue350.0K318.0K311.0K272.0K326.0K155.0K78.0K261.0K188.0K212.0K
Gross profit-350.0K-318.0K-311.0K-272.0K-326.0K-155.0K-78.0K-261.0K-188.0K-212.0K
Research and development154.2M73.3M27.7M24.3M38.4M31.4M20.8M47.9M40.8M39.9M
Selling, general and administrative18.3M17.6M14.1M12.3M12.1M11.4M2.42M1.52M12.2M18.3M
Operating income-172.5M-90.9M-41.8M-36.5M-50.5M-42.8M-23.2M-61.1M-53.0M-58.2M
Depreciation and amortization350.0K318.0K311.0K318.0K326.0K155.0K78.0K261.0K188.0K212.0K
EBITDA-172.1M-90.6M-41.4M-36.2M-50.1M-42.6M-23.1M-60.9M-52.8M-58.0M
Interest expense318.0K326.0K01.77M1.90M165.0K529.0K
Income before tax-165.7M-80.6M-36.9M-35.4M-50.6M-42.5M-23.2M-61.4M-52.0M-57.9M
Income tax0000000000
Net income-165.7M-80.6M-36.9M-35.4M-50.6M-42.5M-23.1M-61.4M-52.0M-57.9M
Earnings per share, basic-1.99-1.32-0.84-1.37-2.95-3.57-3.80-1.90-1.90-2.12
Earnings per share, diluted-1.32-0.84-1.37-2.95-3.57-3.80-1.90-1.90-2.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents85.4M33.2M26.7M26.8M70.1M68.1M1.01M49.3M40.8M32.4M
Short-term investments51.4M150.2M60.0M91.6M024.5M43.0M68.7M61.3M96.8M
Receivables747.0K1.05M332.0K208.0K32.0K158.0K1.54M946.0K347.0K
Inventory-208.0K-32.0K3.16M1
Current assets142.0M195.3M90.2M120.7M72.2M98.0M4.75M121.3M104.9M130.9M
Property, plant and equipment622.0K881.0K684.0K831.0K1.05M1.04M274.0K375.0K528.0K661.0K
Total assets145.8M200.2M95.9M126.4M78.7M104.7M5.20M121.8M105.5M131.6M
Accounts payable5.22M2.42M1.28M1.69M1.66M2.63M3.54M3.59M3.02M2.57M
Current liabilities64.8M24.4M9.51M10.7M8.85M8.99M5.89M13.3M7.29M9.89M
Long-term debt8.46M15.2M20.0M
Total debt4.07M5.12M5.55M5.41M6.00M6.52M14.5M20.0M20.0M3.18M
Total liabilities67.8M28.4M14.2M15.5M14.3M15.0M5.89M28.5M27.3M9.89M
Shareholders' equity78.1M171.8M81.7M110.9M64.4M89.7M-694.0K2.91M78.2M121.7M
Shares outstanding83.1M63.8M43.9M43.3M17.7M15.4M6.09M37.3M27.5M27.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-113.2M-70.8M-33.5M-27.6M-42.1M-42.2M-22.7M-51.5M-43.8M-52.0M
Capital spending-91.0K-515.0K-164.0K-100.0K-333.0K-62.0K-83.0K-108.0K-55.0K-660.0K
Free cash flow-113.3M-71.3M-33.6M-27.7M-42.4M-42.3M-22.8M-51.6M-43.8M-52.6M
Cash from investing100.3M-85.4M33.4M-91.0M24.2M17.1M-83.0K-6.87M35.6M51.4M
Cash from financing65.1M161.9M30.0K75.3M19.9M93.6M19.4M66.9M16.6M-2.71M
Share buybacks75.3M75.6M194.0K67.2M195.0K220.0K
Change in cash52.2M5.74M-76.0K-43.3M1.95M68.5M-3.39M8.55M8.43M-3.24M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
S-8 · Registration statement for employee plansNov 16, 2026Offer documentSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 16, 2026ResultsSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2026Insider tradeSEC
8-K · Current reportSep 29, 2026Management or board changeSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
8-K · Current reportJun 29, 2026Current reportSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 20, 2026Annual reportSEC
DEF 14A · Proxy statementApr 20, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 19, 2026Offer documentSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
8-K · Current reportMar 9, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 2, 2026Big-stake noticeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026Material contractSEC
424B5 · ProspectusFeb 26, 2026Offer documentSEC
424B5 · ProspectusFeb 25, 2026Offer documentSEC
8-K · Current reportFeb 24, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 22, 2026FinancingSEC
8-K · Current reportJan 12, 2026ResultsSEC
8-K · Current reportDec 17, 2025FinancingSEC
8-K · Current reportNov 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
8-K · Current reportOct 14, 2025Current reportSEC
8-K · Current reportSep 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 29, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 31, 2025Big-stake noticeSEC
8-K · Current reportJul 31, 2025Material contractSEC
424B5 · ProspectusJul 30, 2025Offer documentSEC
8-K · Current reportJul 29, 2025ResultsSEC
424B5 · ProspectusJul 29, 2025Offer documentSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 23, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 17, 2025Big-stake noticeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
8-K · Current reportMay 13, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
8-K · Current reportMay 5, 2025Current reportSEC
10-Q · Quarterly reportApr 30, 2025Quarterly reportSEC
8-K · Current reportApr 30, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 16, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 11, 2025Annual reportSEC
DEF 14A · Proxy statementApr 11, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 24, 2025Offer documentSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
8-K · Current reportJan 27, 2025Management or board changeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
8-K · Current reportDec 16, 2024Current reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 6, 2024Big-stake noticeSEC
10-Q · Quarterly reportOct 30, 2024Quarterly reportSEC
8-K · Current reportOct 30, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
8-K · Current reportJun 10, 2024Current reportSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
8-K · Current reportMay 31, 2024Meeting outcomeSEC
8-K · Current reportMay 30, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 28, 2024Other filingsSEC
CORRESP · Letter to the SECMay 22, 2024Other filingsSEC
8-K · Current reportMay 20, 2024Current reportSEC
UPLOAD · Letter from the SECMay 16, 2024Other filingsSEC
S-3 · Registration statementMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedMar 15, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 14, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 14, 2024Offer documentSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
8-K · Current reportMar 14, 2024ResultsSEC
8-K · Current reportMar 11, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 26, 2024Big-stake noticeSEC
8-K · Current reportFeb 16, 2024Material contractSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 16, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 15, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
424B5 · ProspectusFeb 14, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 14, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
424B5 · ProspectusFeb 13, 2024Offer documentSEC
8-K · Current reportFeb 12, 2024ResultsSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipOct 5, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 5, 2023Insider tradeSEC
8-K · Current reportOct 3, 2023Management or board changeSEC
SC 13G · Big-stake noticeAug 18, 2023Big-stake noticeSEC
8-K · Current reportAug 14, 2023Current reportSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
8-K · Current reportJul 25, 2023Current reportSEC
144 · Notice of proposed saleJul 24, 2023Other filingsSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 18, 2023Insider tradeSEC
8-K · Current reportJul 17, 2023Current reportSEC
8-K · Current reportJun 1, 2023Current reportSEC
4 · Change in ownershipMay 18, 2023Insider tradeSEC
4 · Change in ownershipMay 18, 2023Insider tradeSEC
4 · Change in ownershipMay 18, 2023Insider tradeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
8-K · Current reportMay 12, 2023Meeting outcomeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
ARS · Annual report to shareholdersApr 11, 2023Annual reportSEC
DEF 14A · Proxy statementApr 11, 2023Meeting noticeSEC
8-K · Current reportApr 6, 2023Management or board changeSEC
SC 13D/A · Big-stake notice, amendedMar 16, 2023Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 14, 2023Offer documentSEC
S-8 · Registration statement for employee plansMar 14, 2023Offer documentSEC
10-K · Annual reportMar 14, 2023Annual reportSEC
8-K · Current reportMar 14, 2023ResultsSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2023Insider tradeSEC
8-K · Current reportFeb 7, 2023Current reportSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 20, 2023Big-stake noticeSEC
8-K · Current reportJan 9, 2023Current reportSEC

This page holds 200 of 710 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Larimar Therapeutics, Inc.’s releases · as of Nov 10, 2026

Common shares
104,634,619
Fully diluted
104,634,619

Fully diluted

LineSharesAs of
Common shares104,634,619Nov 10, 2026

Share count over time

CountShares
Nov 10, 2026104,634,619
Sep 30, 2026104,634,619

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Deerfield Management Company, L.P.35.6M34.0%US$114MSep 30, 2026
Blue Owl Capital Holdings LP9.92M9.5%US$31.7MSep 30, 2026
Rtw Investments, LP5.82M5.6%US$18.6MSep 30, 2026
BlackRock5.77M5.5%US$18.4MSep 30, 2026
Defilade Capital Management, L.P.4.93M4.7%US$15.8MSep 30, 2026
Vanguard4.87M4.7%US$15.6MSep 30, 2026
Driehaus Capital Management LLC3.13M3.0%US$10MSep 30, 2026
Goldman Sachs2.97M2.8%US$9.49MSep 30, 2026
AQR Capital Management LLC2.24M2.1%US$7.16MSep 30, 2026
Marshall Wace, LLP2.2M2.1%US$7.01MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
DAFNA Capital Management LLC1.89M1.8%US$6.03MSep 30, 2026
Bank of America1.87M1.8%US$5.98MSep 30, 2026
AIGH Capital Management LLC1.85M1.8%US$5.91MSep 30, 2026
Geode Capital1.74M1.7%US$5.57MSep 30, 2026
Millennium1.67M1.6%US$5.33MSep 30, 2026
State Street1.45M1.4%US$4.64MSep 30, 2026
Qube Research & Technologies Ltd1.41M1.4%US$4.52MSep 30, 2026
Woodline Partners LP1.4M1.3%US$4.48MSep 30, 2026
Dimensional1.13M1.1%US$3.61MSep 30, 2026
Fidelity1.09M1.0%US$3.49MSep 30, 2026
Sphera Funds Management LTD.1.04M0.99%US$3.31MSep 30, 2026
Ghisallo Capital Management LLC750K0.72%US$2.4MSep 30, 2026
Alyeska Investment Group, L.P.617K0.59%US$1.97MSep 30, 2026
Hennion & Walsh Asset Management, Inc.570K0.55%US$1.82MSep 30, 2026
D. E. Shaw & Co., Inc.569K0.54%US$1.82MSep 30, 2026
Prudential Financial Inc559K0.53%US$1.79MSep 30, 2026
Northern Trust544K0.52%US$1.74MSep 30, 2026
SummitTX Capital, L.P.406K0.39%US$1.3MSep 30, 2026
JPMorgan310K0.30%US$973KSep 30, 2026
Susquehanna301K0.29%US$963KSep 30, 2026
Burkehill Global Management, LP300K0.29%US$959KSep 30, 2026
Cerity Partners LLC275K0.26%US$878KSep 30, 2026
Gem Investment Advisors, LLC262K0.25%US$838KSep 30, 2026
Wellington242K0.23%US$775KSep 30, 2026
ADAR1 Capital Management, LLC238K0.23%US$760KSep 30, 2026
Two Sigma236K0.23%US$754KSep 30, 2026
UBS216K0.21%US$691KSep 30, 2026
Morgan Stanley214K0.20%US$684KSep 30, 2026
Schwab207K0.20%US$661KSep 30, 2026
Federated Hermes, Inc.189K0.18%US$604KSep 30, 2026
Diadema Partners LP186K0.18%US$593KSep 30, 2026
Renaissance Technologies184K0.18%US$588KSep 30, 2026
Creative Planning177K0.17%US$565KSep 30, 2026
BNY144K0.14%US$460KSep 30, 2026
Nuveen141K0.13%US$450KSep 30, 2026
Invesco135K0.13%US$433KSep 30, 2026
Gsa Capital Partners LLP121K0.12%US$387KSep 30, 2026
Ieq Capital, LLC117K0.11%US$373KSep 30, 2026
Bridgeway Capital Management, LLC90,1320.09%US$288KSep 30, 2026
DWS88,9070.08%US$285KSep 30, 2026

This page holds 50 of 142 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.21M2.1%US$6.73MJun 30, 2026
iShares Russell 2000 ETF1.72M1.6%US$5.26MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF815K0.78%US$2.48MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account758K0.72%US$2.31MJun 30, 2026
Fidelity Small Cap Index Fund727K0.69%US$2.78MJul 31, 2026
Vanguard Extended Market Index Fund699K0.67%US$2.13MJun 30, 2026
Vanguard Explorer Fund659K0.63%US$2.52MJul 31, 2026
iShares Russell 2000 Growth ETF625K0.60%US$1.91MJun 30, 2026
iShares Biotechnology ETF371K0.35%US$1.13MJun 30, 2026
Dimensional U.S. Small Cap ETF341K0.33%US$1.3MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Driehaus Micro Cap Growth Fund339K0.32%US$1.03MJun 30, 2026
Vanguard Russell 2000 Index Fund243K0.23%US$846KMay 31, 2026
iShares Micro-Cap ETF224K0.21%US$682KJun 30, 2026
Fidelity Extended Market Index Fund218K0.21%US$760KMay 31, 2026
JPMorgan Small Cap Value Fund183K0.17%US$558KJun 30, 2026
Adara Smaller Companies Fund165K0.16%US$573KMay 31, 2026
Schwab Small-Cap Index Fund162K0.15%US$619KJul 31, 2026
Vanguard U.S. Momentum Factor ETF152K0.15%US$529KMay 31, 2026
U.S. Micro Cap Portfolio134K0.13%US$513KJul 31, 2026
Master Small Cap Index Series124K0.12%US$380KJun 30, 2026
Small Company Growth Portfolio110K0.11%US$335KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF105K0.10%US$402KJul 31, 2026
U.S. Small Cap Portfolio102K0.10%US$389KJul 31, 2026
VIP Disciplined Small Cap Portfolio99,3910.09%US$303KJun 30, 2026
Nuveen Small Cap Blend Index Fund88,9240.08%US$340KJul 31, 2026
AQR Small Cap Multi-Style Fund76,2630.07%US$233KJun 30, 2026
Fidelity Total Market Index Fund73,2530.07%US$255KMay 31, 2026
EQ/2000 Managed Volatility Portfolio72,4500.07%US$221KJun 30, 2026
SIMT Small Cap Fund66,8200.06%US$204KJun 30, 2026
Fidelity Series Total Market Index Fund63,3680.06%US$221KMay 31, 2026
Fidelity Small Cap Growth Index Fund62,1270.06%US$189KJun 30, 2026
Fidelity Nasdaq Composite Index Fund62,0680.06%US$216KMay 31, 2026
EQ/Small Company Index Portfolio59,5700.06%US$182KJun 30, 2026
Destinations Small-Mid Cap Equity Fund57,6570.06%US$201KMay 31, 2026
LVIP State Street Small-Cap Index Fund49,4000.05%US$151KJun 30, 2026
EQ/AB Small Cap Growth Portfolio48,6500.05%US$148KJun 30, 2026
Federated Hermes MDT Small Cap Core ETF47,0620.04%US$164KMay 31, 2026
JPMorgan Small Cap Value Portfolio45,0210.04%US$137KJun 30, 2026
Schwab Total Stock Market Index Fund44,8390.04%US$171KJul 31, 2026
Vanguard Balanced Index Fund39,3100.04%US$120KJun 30, 2026
Small Cap Value Fund37,2800.04%US$130KMay 31, 2026
Nuveen Equity Index Fund37,2350.04%US$142KJul 31, 2026
Vanguard Russell 2000 Value Index Fund36,2140.03%US$126KMay 31, 2026
Fidelity ZERO Total Market Index Fund35,9120.03%US$137KJul 31, 2026
Ultra-Small Company Market Fund34,9160.03%US$106KJun 30, 2026
Small Cap Index Fund34,5980.03%US$106KJun 30, 2026
U.S. Vector Equity Portfolio33,4040.03%US$128KJul 31, 2026
Global X Russell 2000 ETF31,7800.03%US$121KJul 31, 2026
Siit Small Cap Fund30,3600.03%US$106KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund29,6740.03%US$90,506Jun 30, 2026

This page holds 50 of 130 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Clayton Russell
Officer: Chief Medical Officer
Buy3,322USD 3.01US$9,999Nov 16, 2026
Sherman Jeffrey W
Director
Buy3,289USD 3.06US$10,058Nov 16, 2026
Hamilton Thomas Edward
Director
Buy70,000USD 2.67US$187KNov 12, 2026
Shankar Gopi
Officer: Chief Development Officer
Buy5,000USD 2.71US$13,549Nov 11, 2026
Celano Michael
Officer: Chief Financial Officer
Buy18,460USD 2.71US$49,992Nov 11, 2026
Harlow John B. Jr.
Officer: President and COO
Buy17,800USD 2.80US$49,918Nov 11, 2026
Truitt Joseph
Director
Buy3,500USD 2.80US$9,792Nov 11, 2026
Thomas Frank E
Director
Buy8,000USD 2.73US$21,800Nov 11, 2026
Ben-Maimon Carole
Director, Officer: President and CEO
Buy18,050USD 2.77US$49,953Nov 11, 2026
Hamilton Thomas Edward
Director
Buy50,000USD 3.34US$167KJul 6, 2026

Big stakes

StakeStakeSharesDateFiling
Deerfield Management Company, L.P.34.41%35.7MFeb 27, 2026Schedule 13D
Blue Owl Capital Holdings LP9.99%10.7MMar 31, 2026Schedule 13G
Rtw Investments, LP5.60%5.82MSep 30, 2026Schedule 13G
Opaleye Management Inc.4.80%4.11MAug 29, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Flynn
Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Since at least May 28, 2020
Robert J Perez
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 22, 2023 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past)
Director · Sep 24, 2015 – Jun 26, 2019 · Past
Jeffrey S. Hatfield
Other companies: Vir Biotechnology, Inc. (Chair of the Board · Since at least Dec 9, 2020); Viridian Therapeutics, Inc. (Director · Aug 10, 2017 – Feb 4, 2021 · Past); aTyr Pharma, Inc. (Director · Apr 3, 2017 – May 6, 2020 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 1, 2016 – Jan 19, 2018 · Past); Vitae Pharmaceuticals Inc (Chief Executive Officer, Director · Sep 24, 2014 – Oct 24, 2016 · Past); Ambit Biosciences Corp (Director · Jun 2, 2014 – Nov 10, 2014 · Past)
Chief Executive Officer, Director · Oct 9, 2017 – Jan 22, 2019 · Past
Jonathan Leff
Other companies: BiomX Inc. (Director · Mar 15, 2024 – Apr 14, 2025 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Protara Therapeutics, Inc. (Director · Aug 2, 2017 – Jun 8, 2018 · Past); AveXis Inc (Director · Feb 10, 2016 – Feb 10, 2016 · Past); Alpine Immune Sciences Inc (Director · Jun 16, 2015 – Sep 11, 2015 · Past); InterMune Inc (EVP, Research & Development · Feb 27, 2012 – Sep 29, 2014 · Past)
Director · Since at least May 28, 2020
Kevin P Starr
Other companies: MyoKardia Inc (Director · Oct 28, 2015 – Mar 7, 2018 · Past); Global Blood Therapeutics Inc (Director · Aug 11, 2015 – Aug 17, 2015 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Jun 15, 2023 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Feb 19, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2017 · Past); Human Genome Sciences Inc (Director · May 3, 2007 – Jul 10, 2007 · Past)
Director · Jun 18, 2014 – Sep 24, 2015 · Past
Alicia Secor
Other companies: Zevra Therapeutics, Inc. (Director, Audit Committee, Compensation Committee · Since at least Dec 2, 2025); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Orchard Therapeutics PLC (Director · Jan 1, 2020 – Jan 24, 2024 · Past); GW Pharmaceuticals plc (Director · Oct 1, 2018 – May 5, 2021 · Past); Juniper Pharmaceuticals Inc (President and CEO, Director · Aug 1, 2016 – Aug 14, 2018 · Past)
Chief Commercial Officer · Mar 31, 2016 – Mar 31, 2016 · Past
Thomas Daniel
Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past); Juno Therapeutics Inc (Director · Aug 11, 2015 – Mar 5, 2018 · Past); Epizyme Inc (Director · May 30, 2013 – May 30, 2013 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past)
Director · Mar 3, 2016 – May 12, 2021 · Past
Jeffrey Sherman
Other companies: Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021); Strongbridge Biopharma plc (Director · Jan 1, 2018 – Oct 5, 2021 · Past); Horizon Pharma PLC (EVP and Chief Medical Officer · Jul 28, 2011 – Mar 23, 2018 · Past); Idm Pharma Inc (Sr. VP, R & D and CMO · Aug 29, 2007 – Apr 3, 2008 · Past)
Director · Since at least Oct 3, 2023
Dennis Kim
Other companies: Skye Bioscience, Inc. (Chief Medical Officer · Aug 21, 2019 – Aug 7, 2020 · Past); Sesen Bio Inc (Chief Medical Officer · Dec 3, 2018 – Dec 3, 2018 · Past); Orexigen Therapeutics Inc (Sr. VP, Corporate Development · Feb 27, 2009 – Apr 23, 2009 · Past)
Chief Medical Officer · Jun 18, 2014 – Jan 22, 2019 · Past
Frank E Thomas
Other companies: Spero Therapeutics, Inc. (Director · Since at least Nov 1, 2017); Orchard Therapeutics PLC (See Remarks · Jan 1, 2020 – Jan 24, 2024 · Past); AMAG Pharmaceuticals Inc (President & COO · Feb 23, 2017 – Feb 23, 2017 · Past)
Director · Since at least Jun 30, 2016
All 35 people
PersonSeat
John L. LaMattina
Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least May 31, 2012); Immunome, Inc. (Director · Oct 1, 2020 – Jun 8, 2023 · Past); Human Genome Sciences Inc (Director · May 17, 2012 – Jul 30, 2012 · Past)
Director · Jun 18, 2014 – Jun 26, 2019 · Past
Michael Celano
Other companies: Recro Pharma Inc (Chief Operating Officer · Jul 5, 2016 – Jan 18, 2019 · Past); Kensey Nash Corp (Chief Financial Officer · Mar 10, 2009 – Jun 22, 2012 · Past); OraSure Technologies, Inc. (Director · Oct 4, 2006 – Aug 12, 2022 · Past)
Chief Financial Officer · Since at least May 28, 2020
Peter Barrett
Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026); Synlogic Inc (Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022)
Director · May 10, 2022 – May 10, 2022 · Past
Carole Ben-Maimon
Other companies: Teligent Inc (Director · Mar 29, 2016 – Jul 21, 2021 · Past); Impax Laboratories Inc (President, Global Pharm. · Sep 6, 2011 – May 14, 2014 · Past)
President and CEO, Director · Since at least May 28, 2020
Frank E. Thomas
Other companies: Spero Therapeutics, Inc. (Chairman of the Board; Audit Committee Chair · Since at least Apr 28, 2025)
Director · Since at least Nov 4, 2026
John B Harlow Jr
Other companies: Esperion Therapeutics, Inc. (Chief Commercial Officer · Since at least Nov 17, 2025)
President and COO · Since at least Sep 29, 2026
Joseph Truitt
Other companies: Century Therapeutics, Inc. (Director · Since at least Sep 9, 2026)
BOARD CHAIR · Since at least May 10, 2022
Thomas E Hughes
Other companies: Viridian Therapeutics, Inc. (Director · Feb 13, 2017 – May 21, 2020 · Past)
See Remarks, Director · Jun 18, 2014 – Jun 28, 2018 · Past
Thomas Hamilton
Other companies: Annaly Capital Management Inc. (Director · Since at least Mar 6, 2019)
Director · Since at least May 28, 2020
Adrienne Clements-EganVice President, Bioanalytics and Developability · Since at least Nov 5, 2026
Brian McVeighChief Business Officer · May 29, 2018 – Jan 22, 2019 · Past
Francis Michael ConwayVICE PRESIDENT AND CONTROLLER · Since at least Nov 5, 2026
Frank NazzarioVice President, Commercial · Since at least Nov 4, 2026
Gopi ShankarChief Development Officer · Since at least Feb 7, 2023
Jennifer JohanssonVice President, Legal and Compliance · Since at least Nov 5, 2026
John BermanVice President of Finance and Administration · Since at least Nov 5, 2026
John HarlowPresident and Chief Operating Officer · Since Sep 29, 2026
Keith E. LynchVice President, CMC Technical Operations · Since at least Nov 5, 2026
Mohamed HamdaniVice President, Statistics and Quantitative Sciences · Since at least Nov 5, 2026
Noreen SchererVice President of Clinical Operations · Since at least Nov 5, 2026
Patrick LoustauPresident · Jun 18, 2014 – Mar 31, 2016 · Past
Russell ClaytonChief Medical Officer · Since at least Jul 17, 2023
Rusty ClaytonChief Medical Officer · Since at least Feb 24, 2026
Tom HamiltonDirector · Since at least Jul 8, 2026
Wendy EverettDirector · Jun 26, 2019 – Jun 26, 2019 · Past

Open People

Log in to ask 6ix AI your own questions about Larimar Therapeutics, Inc.